GLP-1 / GIP Dual Receptor Agonist | 10mg Lyophilised Powder
GLP-1 / GIP Dual Receptor Agonist | 10mg Lyophilised Powder
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist originally developed by Eli Lilly under the brand name Mounjaro. Its unique dual-agonist mechanism activates both GIP and GLP-1 receptors synergistically, producing more pronounced effects on insulin secretion, glucagon suppression, and appetite regulation than single-receptor agonists. It represents one of the most significant advances in metabolic research in recent years.
| Target Receptors | GLP-1R + GIPR (Dual Agonist) |
| Molecular Weight | 4813.5 g/mol |
| Purity | ≥98% (HPLC verified) |
| Form | Lyophilised powder |
| Half-life | ~5 days |
| Storage | -20°C, protected from light |
| Quantity | 10mg per vial |
All compounds supplied by Monumental Peptides are independently tested by a third-party laboratory using HPLC and Mass Spectrometry, with purity confirmed at ≥98%. Certificates of Analysis are available upon request — simply contact us after placing your order.
Request Certificate of Analysis →UK stock · Fast dispatch · Full documentation included
Order Now — £54.99 →